NIPH
NBIX icon

NN Investment Partners Holdings’s Neurocrine Biosciences NBIX Stock Holding History

NN Investment Partners Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.35M Sell
14,377
-6,460
-31% -$547K 0.01% 598
2021
Q4 		$1.77M Buy
20,837
+1,102
+6% +$101K 0.01% 562
2021
Q3 		$1.89M Sell
19,735
-11,481
-37% -$1.08M 0.01% 559
2021
Q2 		$3.04M Sell
31,216
-66,546
-68% -$6.38M 0.02% 497
2021
Q1 		$9.51M Sell
97,762
-2,719
-3% -$285K 0.06% 282
2020
Q4 		$9.63M Buy
100,481
+88,945
+771% +$8.59M 0.06% 256
2020
Q3 		$1.11M Hold
11,536
– – 0.01% 581
2020
Q2 		$1.41M Buy
11,536
+3,648
+46% +$403K 0.01% 561
2020
Q1 		$682K Sell
7,888
-2,700
-26% -$264K 0.01% 615
2019
Q4 		$1.14M Buy
+10,588
New +$1.11M 0.01% 591
2018
Q3 		– Sell
-2,651
Closed -$260K – 672
2018
Q2 		$260K Sell
2,651
-1,128
-30% -$101K ﹤0.01% 600
2018
Q1 		$313K Sell
3,779
-297,321
-99% -$25.1M ﹤0.01% 604
2017
Q4 		$23.4M Buy
301,100
+32,158
+12% +$2.19M 0.17% 129
2017
Q3 		$16.5M Buy
268,942
+60,780
+29% +$3.21M 0.1% 173
2017
Q2 		$9.58M Buy
+208,162
New +$10.1M 0.09% 178

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NN Investment Partners Holdings's NBIX Position: Q1 2022 in Review

NN Investment Partners Holdings reduced its Neurocrine Biosciences (NBIX) stake by 31% in Q1 2022, selling an estimated $547K and leaving 14,377 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #598.

NN Investment Partners Holdings first reported a position in NBIX in Q2 2017 and has held it in 15 quarters since. The position peaked at $23.4M in Q4 2017. 427 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

  • NN Investment Partners Holdings held 14,377 shares of Neurocrine Biosciences worth $1.35M as of Q1 2022.
  • NN Investment Partners Holdings sold 6,460 Neurocrine Biosciences shares in Q1 2022, an estimated $547K.
  • Neurocrine Biosciences made up 0.01% of NN Investment Partners Holdings's portfolio in Q1 2022, its #598 holding.
  • NN Investment Partners Holdings first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 15 quarters since.
  • NN Investment Partners Holdings's Neurocrine Biosciences position peaked at $23.4M in Q4 2017.
  • 427 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on NN Investment Partners Holdings's 13F filing for Q1 2022, filed 11 May 2022.